vor 6 Jahren

Berlin to go, english edition 2/2015

  • Text
  • Berlin
  • Healthcare
  • Innovative
  • Scientific
  • Pharmaceutical
  • Germany


DISCUSSION THE FUTURE OF MEDICINE In conversation with Prof. Dr. Karl Max Einhäupl, Chairman of the Charité – Universitätsmedizin Berlin, about the future challenges of the healthcare sector As Europe’s largest university hospital with over 100 clinics in four locations around the capital city, the Charité enjoys an international reputation for excellence in research, clinical development, training and practice. Prof. Dr. Karl Max Einhäupl spoke in an interview with Berlin to go about the duties of modern medicine, the location advantages of the German capital region and the la test issues in the healthcare sector. What subjects are shaping the future of medicine? Prof. Dr. Karl Max Einhäupl (KME): When we talk about the future of medicine, a major topic is the increasing speed with which medical opportunities are growing, whilst their affordability lags behind. We therefore need to think about how we can deal with the diminishing solidarity of the healthcare system. The general public will not be able to finance all of the services in the future. This applies in par ticular to personalised medicine – the second major subject of the future. Because new diagnostic measures, in the form of the molecular sub-differentiation between diseases, constitute an essential foundation of personalised medicine. They provide us with the possibility of providing targeted treatment based on the individuality of the disease and the individuality of the patient. However, this also means that we will be creating an increasing number of rare diseases from widespread diseases. This in turn brings new challenges in terms of affordability. In this context we will require cross-sector treatment approaches – and that is topic number three. The Charité is generating decisive stimuli in the national and international healthcare sector. How is the Charité influencing the future of medicine? KME: The future of medicine is initially dependent on the results of research. The Charité primarily sees itself as an institution that drives innovation in research. Our company objective is to be a world leader in three areas, and to be one of the international frontrunners in a further five to eight photo: Silz – Charité Berlin 12 BERLIN TO GO

DISCUSSION Portrait: Charité Berlin fields. Incidentally, our self-image as an innovation driver also applies to medical teaching. We therefore introduced the model medical educational programme in 2010, which intermeshed basic scientific and clinical knowledge from the outset for the first time. However, in order to influence the future of medicine in the right way we also pose ourselves the question: What does the patient want? There are three answers to this. Firstly: Innovations should arrive at the hospital bed faster. Secondly: Medicine should remain affordable. And thirdly: People desire fair distribution of healthcare products. The Charité therefore participates in numerous political and public dialogues, in order to drive the further development of the healthcare system – the World Health Summit is an excellent example of this. The 7th World Health Summit is set to take place from the 11th to the 13th October in Berlin. This expert summit, with its top-class participants, was initiated by the Charité. What topics will you be addressing at this year’s summit? KME: Every year, the World Health Summit brings together around 1,300 internationally renowned visionaries from research, politics and industry. This year we will once again be tackling an important subject in Ebola, although we will also be applying ourselves to questions of climate change and its effects on human health. We will be looking at the health of refugees and people who are the victims of major natural disasters or conflicts, and we will be examining future-orientated topics, such as healthy ageing and the digital healthcare revolution. The subjects of data management and digitalisation are in creasingly dominating the roles of clinic managers. What does that mean for the Charité with its 100 or more clinics, consolidated within 17 Charité centres at four sites around the city? KME: Digitalisation is a pressing subject like almost no other. On the one hand because we must move away from paper records in healthcare for reasons of quality assurance. And also because we deal with vast quantities of data, in particular when we speak of personalised medicine. We therefore need to specifically prepare ourselves for the subject of big data. The amalgamation of IT and healthcare constitutes a real opportunity – in particular in Berlin, which offers excellent possibilities as an IT capital – and we are therefore deliberately focussing on this field. This also includes a requirement for good data protection mecha nisms. Although absolute data security will not be possible, we must not allow excessive data protection to hamper developments that contribute to improving the provision of healthcare in Berlin and Germany. Whilst we’re speaking of synergies: How does the Charité interlink its research and practical expertise with innovative development approaches from industry? KME: In 2008, with its new board, the Charité stated that one of its company goals was to become the number one partner to industry. Naturally, this doesn’t only mean entering into Prof. Dr. Karl Max Einhäupl in an interview with Berlin to go. partnerships with renowned companies from the pharmaceutical sector and medical engineering. As the capital city for start-ups, Berlin also offers the ideal preconditions for work with small companies. Because we are often unable to finance innovative projects alone, it is particularly important for us to become a more powerful development partner. Let’s talk about Berlin as a healthcare hotspot. In your opinion, what opportunities does the Berlin Institute of Health (BIG) offer for the development of the location, and what inspires you there? KME: Firstly, it is a high accolade indeed that the federal government has chosen Berlin as a pioneer for the cooperation between a university and extra-university institution, namely the Charité and the Max Delbrück Center for Molecular Medicine. Both facilities are top international institutions in their field, and they can utilise synergies in unique way here in Berlin. Our amalgamation is aimed at creating mutual added value and improving the framework conditions for successful translation. That means making research usable for patients. Our key questions are: How can research be made more effective, how can we better validate results? Why do we have a diminishing number of young scientists, and how does the compatibility of science and family work? We also need to organise the transfer of technology more effectively. A major topic area that the BIG will need to focus on in the future is public health. Germany is only in the starting blocks here. Excellent preconditions exist in Berlin, with its healthcare cluster, and we should utilise these in order to define problems together and also solve these together. Perhaps this will enable the capital city to become a European Public Health Hub. Thank you for talking to us. Interview Ines Hein BERLIN TO GO 13

Publications in English

Publikationen auf deutsch